Edwards Lifesciences Corporation
89.07USD
-1.0200 (-1.13%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on EW.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.74▼ | $0.75 | 2 | 15 |
| Next quarter | $0.71▼ | $0.74 | 0 | 1 |
| Current year | $3▼ | $3 | 1 | 0 |
| Next year | $3.38▲ | $3.37 | 1 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.74 | $0.78 | +0.04 (+5.3%) |
| 2026-03-31 | $0.73 | $0.78 | +0.05 (+7.3%) |
| 2025-12-31 | $0.62 | $0.58 | -0.04 (-6.3%) |
| 2025-09-30 | $0.59 | $0.67 | +0.08 (+12.6%) |
506 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Initiated | Overweight | $110 | Oct 7, 2026 |
| BTIG | Reiterated | Buy | $110 | Sep 11, 2026 |
| Leerink Partners | Upgraded from Market Perform | Outperform | $87 $101 | Jul 25, 2026 |
| JP Morgan | Maintained | Overweight | $100 $105 | Jul 24, 2026 |
| Piper Sandler | Reiterated | Overweight | $100 $101 | Jul 24, 2026 |
| Truist Securities | Maintained | Hold | $90 $95 | Jul 16, 2026 |
| Mizuho | Maintained | Outperform | $100 $105 | Jul 15, 2026 |
| RBC Capital | Maintained | Outperform | $100 $110 | Jul 13, 2026 |
| Citigroup | Maintained | Buy | $101 $110 | Jul 8, 2026 |
| Evercore ISI Group | Maintained | Outperform | $93 $100 | Jul 6, 2026 |
| BTIG | Maintained | Buy | $100 $110 | Jun 30, 2026 |
| RBC Capital | Reiterated | Outperform | $100 | Jun 16, 2026 |
| TD Cowen | Maintained | Buy | $97 $104 | Jun 2, 2026 |
| Barclays | Maintained | Overweight | $104 $110 | Apr 27, 2026 |
| Evercore ISI Group | Maintained | Outperform | $92 $93 | Apr 24, 2026 |
| Truist Securities | Maintained | Hold | $89 $90 | Apr 24, 2026 |
| Canaccord Genuity | Maintained | Hold | $87 $85 | Apr 24, 2026 |
| BTIG | Maintained | Buy | $98 $100 | Apr 24, 2026 |
| Baird | Maintained | Neutral | $85 $87 | Apr 24, 2026 |
| Mizuho | Maintained | Outperform | $100 $95 | Apr 13, 2026 |
| Evercore ISI Group | Maintained | Outperform | $94 $92 | Apr 6, 2026 |
| Goldman Sachs | Maintained | Buy | $108 $95 | Feb 11, 2026 |
| Piper Sandler | Reiterated | Overweight | $98 $100 | Feb 11, 2026 |
| Truist Securities | Maintained | Hold | $92 $89 | Feb 11, 2026 |
| Wells Fargo | Maintained | Overweight | $96 $100 | Feb 11, 2026 |
165 filings from 22 insiders · 34 buy / 21 sell over 6m
Officers and directors of EW, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lippis Daniel J.Officer, CVP, TAVR | ExerciseEmployee Stock Option (Right to Acquire) | 619 | — | — | Oct 8, 2026 |
| Lippis Daniel J.Officer, CVP, TAVR | Sell | 619 | $85.65 | $53k | Oct 8, 2026 |
| Lippis Daniel J.Officer, CVP, TAVR | Exercise | 619 | $72.68 | $45k | Oct 8, 2026 |
| Markowitz WayneOfficer, CVP, JAPAC | Tax | 568 | $84.37 | $48k | Sep 14, 2026 |
| Dahl Andrew M.Officer, SVP, Corporate Controller | Tax | 253 | $84.37 | $21k | Sep 13, 2026 |
| Lippis Daniel J.Officer, CVP, TAVR | Exercise | 619 | $72.68 | $45k | Sep 11, 2026 |
| Lippis Daniel J.Officer, CVP, TAVR | Sell | 619 | $87.51 | $54k | Sep 11, 2026 |
| Lippis Daniel J.Officer, CVP, TAVR | ExerciseEmployee Stock Option (Right to Acquire) | 619 | — | — | Sep 11, 2026 |
| Chopra DaveenOfficer, CVP, TMTT, Surgical & IHFM | Tax | 398 | $86.77 | $35k | Sep 11, 2026 |
| Markowitz WayneOfficer, CVP, JAPAC | Tax | 355 | $86.77 | $31k | Sep 11, 2026 |
| Dahl Andrew M.Officer, SVP, Corporate Controller | Sell | 544 | $91.06 | $50k | Aug 31, 2026 |
| BRULS ANNETTEOfficer | Sell | 2.6k | $89.98 | $238k | Aug 28, 2026 |
| CHOPRA DAVEENOfficer | Sell | 31.8k | $90.99 | $2.89M | Aug 26, 2026 |
| MARKOWITZ WAYNEOfficer | Sell | 1.2k | $91.46 | $113k | Aug 26, 2026 |
| CHOPRA DAVEENOfficer | Exercise | 31.8k | $72.68 | $2.31M | Aug 26, 2026 |
| LIPPIS DANIEL JOfficer | Sell | 619 | $92.03 | $57k | Aug 11, 2026 |
| LIPPIS DANIEL JOfficer | Exercise | 619 | $72.68 | $45k | Aug 11, 2026 |
| MARKOWITZ WAYNEOfficer | Sell | 146 | $86.03 | $13k | Jul 30, 2026 |
| MARKOWITZ WAYNEOfficer | Sell | 9.6k | $85.06 | $819k | Jul 28, 2026 |
| MARKOWITZ WAYNEOfficer | Exercise | 9.6k | $74.02 | $713k | Jul 28, 2026 |
No analyst notes on EW yet.
Analyst Ratings
27 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 18 | 7 | 0 | 0 | Buy2.07 |
| 1 mo ago | 4 | 18 | 7 | 0 | 0 | Buy2.10 |
| 2 mo ago | 4 | 18 | 7 | 0 | 0 | Buy2.10 |
| 3 mo ago | 4 | 18 | 7 | 0 | 0 | Buy2.10 |
Members whose judged calls on EW have played out most reliably.
No settled calls on EW yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice